{
    "clinical_study": {
        "@rank": "164861", 
        "acronym": "ALFA1200", 
        "arm_group": {
            "arm_group_label": "Core study therapy", 
            "description": "idarubicin for both induction and consolidation courses\nif Cr, two cycles of IDAC alone (1.5g/m2 per infusion every 12hours, on D1, 3 and 5 of each cycle)"
        }, 
        "brief_summary": {
            "textblock": "The main objective of this observational survey is to estimate the incidence, the typology,\n      and the evolution of patients with acute myelobalstic leukemia, aged more than 60 years old.\n      In this age group (aged more than 60y), three groups of patients with very different\n      response rates and late outcome can be delineated with specific standard chemotherapy."
        }, 
        "brief_title": "Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia", 
        "completion_date": {
            "#text": "November 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloblastic Leukemia", 
            "Aged Higher Than 60 Years Old"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 60 years or more\n\n          -  With a morphologically proven diagnosis of AML according to WHO 2008 classification\n\n          -  Not previously treated for AML\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  APL in the WHO classification.\n\n          -  Ph1-positive AML or prior Ph1-positive disease\n\n          -  AML evolving from a prior MPN in the WHO 2008 classification.\n\n          -  Prior tumor, if not stable for at least two years, except in-situ carcinoma and skin\n             carcinoma\n\n          -  ECOG Performance Status Score > 3\n\n          -  Positive serology for HIV or HTLV1, or active viralinfection for HBV and HBC.\n\n          -  Severe uncontrolled infection at inclusion time.\n\n          -  Psychiatric disease or an history of non-complianceto medical regimens or patients\n             considered potentially unreliable.\n\n          -  Absence of Health Care Insurance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "hospital admissions from the participating centres"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01966497", 
            "org_study_id": "NI11020"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "AML", 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "contact": {
                "email": "claude.gardin@avc.aphp.fr", 
                "last_name": "Claude Gardin, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Bobigny", 
                    "country": "France", 
                    "state": "Ile de France", 
                    "zip": "93"
                }, 
                "name": "Avicenne"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Observational Study of Patients Older Than 60 Years and With Acute Myeloblastic Leukemia Who Are Administered Standard Chemotherapy Based on Idarubicine-cytarabine", 
        "overall_contact": {
            "email": "herve.dombret@sls.aphp.fr", 
            "last_name": "Herv\u00e9 Dombret, MD PhD", 
            "phone": "33 1 4249 49 49"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "failures include\nresistant disease defined according to the IWG AML response criteria\nhypoplastic marrow after D42 and absence of myeloidrecovery\nearly relapse up to 9 months from CR : Either AML relapse as in the IWG classification or MDS relapse", 
            "measure": "cumulative incidence of failures", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01966497"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "response rate", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Either AML relapse as in the IWG classification\n- Or MDS relapse defined for this study as follows: (i) Persistent cytopenias, if unexplained by other cause, and (ii) myelodysplastic marrow with less than 20% marrow blasts in two samples taken 3 months apart", 
                "measure": "relapse rate", 
                "safety_issue": "No", 
                "time_frame": "within 2 years after inclusion"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "within 2 years after inclusion"
            }, 
            {
                "measure": "adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "within 2 years after inclusion"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}